Cargando…
2288. Adherence to Hepatitis B Screening and Treatment Guidelines in Oncology Patients Starting Anti-CD20 Therapy
BACKGROUND: Hepatitis B virus (HBV) reactivation is a common complication in the treatment of oncology patients when using anti-CD20 monoclonal antibodies (MABs) such as rituximab, obinituzumab, and ofatumumab. In such patients, the reaction of HBV is seen in up to 70% who are HBV DNA positive. Anti...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253205/ http://dx.doi.org/10.1093/ofid/ofy210.1941 |